This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.

Browse

Quercetin

Dietary flavonoid from onions, apples, capers, and tea — a competent mast cell stabilizer + modest antihypertensive that's massively under-delivered by the standard aglycone capsule (≈1–2% bioavail…

Aliases (1)
QUERCETIN
TYPICAL DOSE
| Quercetin aglycone
ROUTE
CYCLE
STORAGE

Overview

What is Quercetin?

Dietary flavonoid from onions, apples, capers, and tea — a competent mast cell stabilizer + modest antihypertensive that's massively under-delivered by the standard aglycone capsule (≈1–2% bioavailability). 500–1000 mg/day of plain quercetin is mostly a vitamin-C-tier hedge; Quercefit phytosome 250–500 mg/day or quercetin-3-O-glucoside from Sophora japonica is what makes the molecule actually hit plasma. Two interesting use cases: seasonal allergic rhinitis (Mlcek 2016 mechanistic + small RCTs — real but moderate effect) and research-grade senolytic when paired with dasatinib in the Mayo Clinic D+Q protocol (Justice 2019 IPF pilot, Hickson 2019 diabetic CKD — proof-of-concept only, requires Rx dasatinib). For Dylan: OPTIONAL-ADD during allergy season at phytosome dose; not core daily stack. Watch warfarin (don't), watch levothyroxine timing (separate ≥4 hr).

Pharmacokinetics

·
PeakHalf-life
Approximate curve — visual aid only, not data-precise PK

Research Indications

Most Effective

NF-κB inhibition

blocks IκB phosphorylation, suppressing transcription of TNF-α, IL-1β, IL-6, IL-8, COX-2, iNOS in macrophages and epithelial cells.

Effective

Nrf2 activation

induces phase-II antioxidant defenses (HO-1, NQO1, glutathione synthesis enzymes) via Keap1-Nrf2-ARE pathway.

Investigational

Direct ROS scavenging

the catechol B-ring and 3-OH/4-keto motif make quercetin a competent peroxyl-radical sink; also chelates Fe²⁺/Cu²⁺ which prevents Fenton-…

Peptide Interactions

Bromelain (250 mg with each 500 mg quercetin):
Synergistic

Classic "natural antihistamine" stack. Bromelain (pineapple enzyme) may modestly enhance quercetin absorption and adds independent anti-inflammatory effect (…

Vitamin C (500 mg):
Synergistic

Recycles oxidized quercetin back to active form; adds independent antihistamine effect via cofactor role in histamine degradation. The Linus Pauling vitamin-…

Resveratrol:
Synergistic

Adjacent polyphenol with overlapping anti-inflammatory and senescence-modifying mechanisms; both poorly bioavailable as aglycones. The combo is more marketin…

Fisetin:
Synergistic

Related senolytic flavonoid (apples, strawberries). Used at high doses (1.5 g/day, 2 consecutive days/month) in the planned Mayo Clinic senolytic protocols. …

Curcumin (already in Dylan's V4):
Synergistic

Independent NF-κB inhibitor + COX-2 inhibitor. Complementary anti-inflammatory profile. Both share poor aglycone bioavailability; both benefit from phytosome…

NAC (community signal: 119 co-mentions):
Synergistic

Cysteine donor / glutathione precursor — pairs with quercetin's Nrf2 induction. Also relevant for the antiviral / COVID-era stack rationale.

Omega-3 (community signal: 138 co-mentions):
Synergistic

Resolvin-pathway synergy on inflammation resolution; no direct interaction.

Quinolone antibiotics (ciprofloxacin, levofloxacin)
Avoid

quercetin inhibits bacterial DNA gyrase weakly; theoretically could affect antibiotic activity (mostly speculative).

High-dose curcumin + quercetin together with iron supplements
Avoid

both are iron chelators; could compound absorption interference. Separate by 2 hours.

Levothyroxine
Avoid

see Drug Interactions; mandatory ≥4-hour separation.

What to Expect

  • Week 1
    Tolerability and dose-response.
  • Week 2-4
    Early effect window.
  • Week 4-8
    Peak benefit assessment.
  • Week 8+
    Cycle decision point.

Side Effects & Safety 7

Side Effects

  1. 1Headache — most frequent acute side effect, often at first dose or above 1000 mg. Usually transient.
  2. 2GI upset — nausea, gastric discomfort, occasionally diarrhea, mostly on empty stomach or at >1500 mg single dose.
  3. 3Tingling in extremities — reported at higher doses; mechanism unclear.
  4. 4Dizziness
  5. 5Fatigue (community signal — 28 reports in dopamine.club)
  6. 6Mild anxiety / sleep disruption (community signal in some users; mechanism unclear, possibly histamine rebound or anti-anxiolytic effect of reduced inflammatory cytokines)
  7. 7Reduced appetite

When to Stop

  • Acute kidney injury at IV-research doses (>1.4 g/m²) — quercetin precipitates renal injury at intravenous doses used in oncology trials. Not a risk with oral supplementation at biohacker doses; flagged for completeness.
  • Hemolysis in G6PD deficiency — theoretical; quercetin is a pro-oxidant at high concentrations. Caution if known G6PD-deficient.
  • Hypothyroidism — chronic high-dose, animal data: Quercetin in rats at very high doses suppressed thyroid peroxidase and reduced T4. Not documented in humans at supplement doses, but interferes with levothyroxine absorption (see Drug Interactions).
  • Iron-overload concern: Quercetin chelates iron — could theoretically worsen iron deficiency in marginal-iron-status individuals (relevant for menstruating women with low ferritin). Hemochromatosis is more nuanced — chelation could be beneficial. Discuss with clinician if either applies.
  • Avoid in late pregnancy — possible uterotonic effect at high doses; insufficient human data.
  • Lactation — insufficient data; default to avoid.
  • First 2 weeks: GI tolerance / headache calibration. If either persists beyond 14 days, switch from aglycone to phytosome (often resolves) or reduce dose.
  • First 30 days if on levothyroxine: Recheck TSH at 8 weeks to confirm no clinical hypothyroidism creep from absorption interference.
  • Chronic use: No specific monitoring beyond what an athletic 20yo's annual bloodwork already covers.

References

Serban et al. 2016 — Effects of quercetin on blood pressure: systematic review + meta-analysis (PMID 27405810)

pubmed.ncbi.nlm.nih.gov · 2016

canonical BP meta; ≥500 mg/day dose threshold.

View Study

Popiołek-Kalisz & Fornal 2022 — quercetin BP meta-analysis update (PMID 35948195)

pubmed.ncbi.nlm.nih.gov · 2022

10 RCTs / 841 participants; confirms Serban.

View Study

Arabi et al. 2023 — umbrella review of cardiometabolic outcomes (PMID 37654199)

pubmed.ncbi.nlm.nih.gov · 2023

current top-tier synthesis; BP and insulin yes, lipids/CRP/glucose equivocal.

View Study

Liu et al. 2025 — quercetin bioavailability meta-analysis (PMID 40037045)

pubmed.ncbi.nlm.nih.gov · 2025

31 human PK studies; phytosome/cyclodextrin → 10–60× plain aglycone.

View Study

Justice et al. 2019 — D+Q senolytics in IPF first-in-human pilot (PMID 30616998)

pubmed.ncbi.nlm.nih.gov · 2019

dasatinib 100 mg + quercetin 1250 mg, 3 days/week × 3 weeks; physical-function improvements.

View Study
Was this helpful?
Your feedback shapes what we research deeper.

How was your experience with this compound?

Anonymous · one vote per session · results below at 5+ votes.

Loading…

See something off?

Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.

Discussion — click to load
Loading…
Continue: Extended research →
Our verdict, decision matrix, deep dives, controversies, sources